Juvenile Psoriatic Arthritis: Risankizumab Study

We are studying a new treatment called risankizumab for children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if it is safe and effective compared to an existing medication.

>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboCost ReimbursementInvestigational MedicinesInjectionDermatologyPediatricsRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Humira
Humira is a medicine that reduces inflammation by calming the immune system to treat autoimmune conditions such as arthritis and Crohn’s disease.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Adalimumab
Adalimumab is a biologic that blocks a key inflammatory protein (TNF) to reduce inflammation in autoimmune conditions like rheumatoid arthritis and Crohn's disease.
Infliximab
Infliximab is a substance that reduces inflammation by blocking a protein called TNF and is used for autoimmune conditions like rheumatoid arthritis and Crohn's.
Risankizumab
Risankizumab is a substance that blocks a specific immune signal to reduce skin inflammation in people with moderate to severe plaque psoriasis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

AbbV-066

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Amgevita
Amsparity
Hefiya

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Pellegrin Hospital
Bordeaux, France
Bicetre Hospital
Croulebarbe, France
HELIOS Klinikum Berlin-Buch GmbH
Klinik fuer Kinder und Jugendmedizin
Bernau bei Berlin, Germany
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.